JOHNSON & JOHNSON

Trading Ideas Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 06:00:00 2024-06-18 pm EDT			5-day change	1st Jan Change
19.69 ^CAD	+0.87%		+1.13%	-6.90%

03:38pm	Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	MT
02:42pm	Johnson & Johnson Sees Positive Trial Results for Tremfya	DJ

Trading Ideas

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

JOHNSON & JOHNSON :An end to the technical rebound lies ahead	19-11-27
JOHNSON & JOHNSON :The underlying trend is to the upside	17-06-12
JOHNSON & JOHNSON :Expect the comeback of a strong trend	17-05-10
JOHNSON & JOHNSON :Buying pressure	16-12-22
JOHNSON & JOHNSON :A good level to buy	16-09-12
JOHNSON & JOHNSON :Towards historic highs	12-09-26
JOHNSON & JOHNSON :Beginning of a bearish movement	12-06-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST

Protect and grow your investments with the help of our experts

Securing my Investments

fermer